All In Biotech

NDA 019430 · Viatris

Epipen E Z Pen

Epinephrine · Intramuscular, Intramuscular, Subcutaneous · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine

Last checked: Nov 20, 2026Latest source record: Mar 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1987

Dec 22, 1987

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,347

454 Phase 3, 232 recruiting

FAERS reports

65,115

37,014 serious, 4,036 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 12, 2026.

Epinephrine injection, USP auto-injectors are indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis to stinging insects (e.g., order Hymenoptera, which include bees, wasps, hornets, yellow jackets and fire ants) and biting insects (e.g., triatoma, mosquitoes), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g., radiocontrast media) and other allergens, as well as idiopathic anaphylaxis or exercise-induced anaphylaxis. Epinephrine injection, USP auto-injectors are intended for immediate administration in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions. Anaphylactic reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria or angioedema. Epinephrine injection, USP auto-injectors are intended for immediate administration as emergency supportive therapy only and are not a substitute for immediate medical care. Epinephrine injection, USP auto-injector is a non-selective alpha and beta-adrenergic receptor agonist indicated in the emergency treatment of allergic reactions (Type I) including anaphylaxis. ( 1 )

Mechanism: Epinephrine acts on both alpha- and beta-adrenergic receptors.

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Dec 22, 1987 Original approval · Type 5 - New Formulation or New Manufacturer
4 products under this application
  • EPIPEN E Z PEN · EPINEPHRINE 0.3MG/DELIVERY · INJECTABLE, INTRAMUSCULAR · Discontinued
  • EPIPEN · EPINEPHRINE 0.3MG/DELIVERY · INJECTABLE, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE AB
  • EPI E Z PEN JR · EPINEPHRINE 0.15MG/DELIVERY · INJECTABLE, INTRAMUSCULAR · Discontinued
  • EPIPEN JR. · EPINEPHRINE 0.15MG/DELIVERY · INJECTABLE, INTRAMUSCULAR, SUBCUTANEOUS · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.

All 2,347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective5,929
  • headache4,422
  • fatigue4,074
  • sinusitis4,052
  • dyspnoea3,477
  • nausea3,396
  • pain3,365
  • product dose omission issue3,247
  • off label use2,904
  • pneumonia2,668
  • covid-192,631
  • cough2,285

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004160
2005146
2006167
2007233
2008352
2009360
2010536
20111,018
2012819
2013713
20141,430
20152,554
20166,749
20173,571
20183,419
20194,195
20207,414
20214,941
20224,661
20234,945
20245,804
20256,158
20264,767

Recalls

7 FDA enforcement reports for this application.

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Apr 13, 2022 · Class II · Terminated

    cGMP deviations: Temperature abuse

  • Mar 15, 2021 · Class II · Terminated

    CGMP Deviations: Intermittent exposure to temperature excursion during storage.

  • Mar 12, 2017 · Class I · Ongoing

    Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication

  • Mar 12, 2017 · Class I · Ongoing

    Defective Delivery System; reports of the device failing to activate which could result in a patient not receiving medication

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,529 on PubMed

Sponsor: Viatris · Also marketed as Epipen, Epi E Z Pen Jr, Epipen Jr.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.